IKT icon

Inhibikase Therapeutics (IKT)

NASDAQ

$1.80

-$0.0100 (

-0.55%

)

1D
5D
1M
6M
1Y
5Y
Market closed

IKT: $1.80 / ₿ 0 BTC / 2686 Sats

1D
5D
1M
6M
1Y
5Y

Key statistics

$1.81
$1.33 - $2.37
$237.00M
1.31
$1.76
$761,137.79
132.03M
$1.00 - $3.98
$1.73 - $1.83
No

What is Inhibikase Therapeutics (IKT)?

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

The Inhibikase Therapeutics (IKT) stock price has been falling

The Inhibikase Therapeutics, Inc. Common Stock (IKT) stock price today is $1.80, reflecting a -0.55% move since the market opened. The company’s market capitalization stands at $237.00M, with a daily trading volume of $761.14K shares. For investors tracking price trends, Inhibikase Therapeutics, Inc. Common Stock stock has ranged between $1.73 and $1.83 today. The previous closing price was $1.81.

Get started with Inhibikase Therapeutics (IKT)

Ready to get started? Follow the steps below, or read our guide on how to buy Inhibikase Therapeutics stock on Kraken starting from $10.

Create an account

Create an account

Open the Kraken app to confirm your eligibility and follow the steps for account verification.



Deposit funds

Deposit funds

Once your account has been verified and stock trading is unlocked, you can deposit funds into your account using your preferred payment method.

Buy

Buy IKT

Search for IKT in the Kraken app, enter the amount you want to invest, review the important details and tap Confirm to place an order to buy IKT.

IKT FAQs

IKT is in the Healthcare sector. Sector is a broad classification that groups companies based on their business activities, industry focus or economic function.

IKT is in the Biotechnology industry. Industry is a more specific classification within a sector, grouping companies that operate in a similar field and have closely related business models.

Over the past 52 weeks, Inhibikase Therapeutics, Inc. Common Stock (IKT) has traded between a low of $1.33 and a high of $2.37.

IKT is in the Biotechnology industry group. Industry group is a further subdivision within an industry, grouping companies with even more closely related business models and operations. This helps investors analyze stocks at a more detailed level than sector and industry classifications alone.

Want to invest in Inhibikase Therapeutics? 
Get the Kraken app

Eligible US clients can now invest in over 11,000 stocks and ETFs - commission-free* - directly in the Kraken app. Download it and get started.

Fictional stock
USD icon
USD
IKT icon
IKT

Only available to USA clients through the Kraken app
or Kraken Pro.

Get the Kraken Pro app and buy Inhibikase Therapeutics in minutes

Kraken App QR Code

Explore other stocks

Most active

Explore the most-traded stocks today

AIXI icon

AIXI

SKYQ icon
NVDA icon

NVDA

Top gainers

Browse today’s biggest stock market winners

Top losers

Compare the worst-performing stocks of 
the day

ARVLF icon

ARVLF

SDCCQ icon
YOTAR icon

YOTAR

APCXW icon
LPCN icon

LPCN

Want to learn more about equities?

Check out our Kraken Learn Center guides

Currently available in the U.S. only; may not be available in all states. Brokerage services are provided by Kraken Securities LLC, member FINRA/SIPC. Please view the firm’s profile, registration and background of our registered reps on https://brokercheck.finra.org/. Digital asset services offered by Payward Interactive, not a member of FINRA/ SIPC and not FDIC insured. This is not an offer, solicitation, inducement or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Kraken Securities is not registered. All trading involves risk, including loss of your investments. View full disclosures at: Equities Disclosures and Crypto Risk Disclosures.

*Other applicable fees may apply.